Hims & Hers Health Registered (A) WKN: A2QMYY ISIN: US4330001060 Kürzel: HIMS Forum: Aktien Thema: Hauptdiskussion

Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million

Ausblick mies? Warum will die Aktie nicht. Bei dem Beat.

Die 700% sind wirklich extrem stark. Wahnsinn was Hims da für Zahlen vorgelegt hat. Einfach alles übertroffen.

Wird noch ins minus drehen. Warum kann es hier kickt mal bei den guten zahlen einfach 10% hochgehen und bleiben

EPS um 700% übertroffen, aber rutscht ins Minus. Wahrscheinlich sell on good news

Hims & Hers Health Q3 2024 Adj EPS $0.32 Beats $0.04 Estimate, Sales $401.60M Beat $382.20M Estimate

Third Quarter 2024 Financial Highlights Revenue was $401.6 million for the third quarter of 2024 compared to $226.7 million for the third quarter of 2023, an increase of 77% year-over-year. Gross margin was 79% for the third quarter of 2024 compared to 83% for the third quarter of 2023. Net income was $75.6 million for the third quarter of 2024, which included a $60.8 million tax benefit related to the release of a tax valuation allowance, partially offset by current period tax expense. This compared to a net loss of $(7.6) million for the third quarter of 2023. Adjusted EBITDA was $51.1 million for the third quarter of 2024 compared to $12.3 million for the third quarter of 2023. Net cash provided by operating activities was $85.3 million for the third quarter of 2024 compared to $25.2 million for the third quarter of 2023. Free Cash Flow was $79.4 million for the third quarter of 2024 compared to $19.3 million for the third quarter of 2023.

Und palantir Schießt hoch. Same Same

Wird sich wahrscheinlich wieder bei 19€ finden. Sollten locker eigentlich +10% sein. Oder übersehe ich was

https://investors.hims.com/news/news-details/2024/Hims--Hers-Health-Inc.-Reports-Third-Quarter-2024-Financial-Results/default.aspx

Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million

6% plus, zahleb raus?

Auf einen schönen Feierabend!

Ich habe 14h Arbeit hinter mir. Ein süßes Finale des Tages wäre schon schön 🙃

Boa, hoffentlich geht es in die richtige Richtung :)

Hims and Hers Health options imply 17.0% move in share price post-earnings